Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease

Table 4 Adverse events and compliance n (%)

Adverse events	MOX-ST(n = 78)	CLA-ST(n = 77)	P value
Bloating/dyspepsia	4 (5.1)	4 (5.3)	0.383
Taste distortion	3 (3.8)	5 (6.4)	0.316
Epigastric discomfort	2 (2.6)	5 (6.4)	0.296
Nausea	1 (1.3)	1 (1.3)	0.505
Abdominal pain	0 (0.0)	1 (1.3)	0.309
Diarrhea	0 (0.0)	3 (3.9)	0.075
Constipation	0 (0.0)	0 (0.0)	NS
Total	10 (12.8)	19 (24.6)	0.038
Compliance, n (%)	78 (100.0)	77 (100.0)	NS

MOX-ST: 14-d moxifloxacin-based sequential therapy; CLA-ST: 14-dclarithromycin-based sequential therapy; NS: Not significant.